Barclays PLC Boosts Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Barclays PLC increased its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 21.5% in the third quarter, HoldingsChannel.com reports. The fund owned 70,167 shares of the company’s stock after acquiring an additional 12,418 shares during the period. Barclays PLC’s holdings in Kyverna Therapeutics were worth $343,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C lifted its position in shares of Kyverna Therapeutics by 35.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock worth $14,872,000 after purchasing an additional 520,663 shares during the period. Novo Holdings A S raised its stake in Kyverna Therapeutics by 5.7% in the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock worth $9,046,000 after buying an additional 100,000 shares in the last quarter. Millennium Management LLC lifted its holdings in Kyverna Therapeutics by 32.8% in the second quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock worth $6,923,000 after buying an additional 227,988 shares during the period. Great Point Partners LLC lifted its holdings in Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after buying an additional 349,152 shares during the period. Finally, MBB Public Markets I LLC bought a new stake in Kyverna Therapeutics during the 2nd quarter valued at approximately $3,076,000. Institutional investors own 18.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KYTX. HC Wainwright lowered their target price on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Wells Fargo & Company lowered their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw began coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price target for the company. Finally, UBS Group started coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Price Performance

Shares of KYTX opened at $4.10 on Friday. Kyverna Therapeutics, Inc. has a twelve month low of $3.54 and a twelve month high of $35.06. The firm has a 50 day moving average of $4.65 and a 200 day moving average of $6.29.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter. On average, equities research analysts predict that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.